Background
==========

Antagonist antibodies targeting CD28 have been proposed as an alternative to the use of CD80/86 antagonists to modulate T cell responses in autoimmunity and transplantation. Advantages would be the blockade of CD28-mediated co-stimulatory signals without impeding co-inhibitory signals depending on CD80 interactions with CTLA-4 and PD-L1 that are important for the control of immune responses and for the function of regulatory T cells. Anti-CD28 antibodies are candidate antagonists only if they prevent access to the CD80/86 ligands without simultaneously stimulating CD28 itself, a process that is believed to depend on receptor multimerization.

Methods and results
===================

In this study, we used different formats of a potentially antagonist anti-human CD28 antibody and evaluated the impact on T cell activation of valency and of the presence of a fragment cristallisable (Fc) domain, two components that might impact receptor multimerization either directly or in the presence of accessory cells expressing Fc receptors. Among monovalent (Fab', scFv), divalent (Fab'2), monovalent-Fc (Fv-Fc) and divalent-Fc (IgG) formats, only the monovalent formats showed consistent absence of induced CD28 multimerization and of associated activation of Phospho Inositol-3 Kinase as well as clear antagonist properties in T cell stimulation assays. In contrast divalent antibodies showed agonist properties resulting in cell proliferation and cytokine release, in a Fc-independent manner. Conjugation of monovalent antibodies with polyethylene glycol, with a molecule of alpha-1-antitrypsin or with an Fc domain significantly extended their in vivo half-life without modifying antagonist properties.

Conclusion
==========

These data indicate that monovalency is mandatory for maintaining antagonistic activity of anti-CD28 monoclonal antibodies.
